Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ
Mari Mino-Kenudson1, Eugene J Mark
1Department of Pathology, Massachusetts General Hospital, 55 Fruit St, Warren 122, Boston, MA 02114, USA. mminokenudson@partners.org
Context:
Non-small cell lung cancer (NSCLC) is a poor-prognosis malignancy for which more effective treatments are needed, with accumulating clinical experiences supporting benefits of receptor tyrosine kinase inhibitors for patients with tumors harboring an epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase ( ALK ) rearrangement.
Objective:
To review completed and ongoing clinical trials of EGFR tyrosine kinase inhibitors for EGFR mutation-positive NSCLC and an ALK inhibitor for those with ALK rearrangement, while also exploring practical issues surrounding the implementation of molecular testing as a routine component of the diagnostic workup of NSCLC in the United States.
Data Sources:
Published biomedical literature, abstracts presented at recent major oncology meetings, and ClinicalTrials.gov.
Conclusions:
Continually evolving evidence indicates the possible efficacy of molecularly targeted agents for the treatment of advanced NSCLC, especially adenocarcinoma. To identify patients who will most likely benefit from the targeted therapy, routine determination of the corresponding genetic alterations after histologic diagnosis of NSCLC (reflex molecular testing for EGFR mutations and ALK rearrangement) should be considered.
Insights
Targeted therapies show promise for non-small cell lung cancer (NSCLC) patients with specific genetic mutations. Routine molecular testing for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements is recommended for optimal treatment selection.
Area of Science:
- Oncology
- Molecular Diagnostics
- Pharmacogenomics
Background:
- Non-small cell lung cancer (NSCLC) has a poor prognosis, necessitating improved treatment strategies.
- Receptor tyrosine kinase inhibitors demonstrate efficacy in NSCLC patients with specific genetic alterations.
- Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are key targets for therapy.
Purpose of the Study:
- To review clinical trials of EGFR and ALK inhibitors for NSCLC.
- To explore the implementation of molecular testing in NSCLC diagnostics in the US.
- To assess the role of targeted therapies in advanced NSCLC treatment.
Main Methods:
- Literature review of published biomedical studies.
- Analysis of abstracts from major oncology meetings.
- Inclusion of data from ClinicalTrials.gov.
Main Results:
- Accumulating evidence supports the use of targeted agents in advanced NSCLC, particularly adenocarcinoma.
- EGFR tyrosine kinase inhibitors are effective for EGFR mutation-positive NSCLC.
- ALK inhibitors show benefit for patients with ALK rearrangement-positive NSCLC.
Conclusions:
- Molecularly targeted agents offer potential efficacy for advanced NSCLC.
- Routine molecular testing (EGFR mutations, ALK rearrangement) is crucial for patient selection.
- Reflex molecular testing should be considered in the diagnostic workup of NSCLC.
